Author:
Lee Soo Jung,Gasche Mitchell B.,Burrows Connor J.,Kondepudi Akhil,Zhang Xiaojie,Wang Michael M.
Abstract
AbstractAntibodies raised in peptide-immunized rabbits have been used in biological research for decades. Although there has been wide implementation of this approach, specific proteins are occasionally difficult to target for multiple reasons. One consideration that was noted in mice is that humoral responses may preferentially target the carboxyl terminus of the peptide sequence which is not present in the intact protein. To shed light on the frequency of preferential rabbit antibody responses to C-termini of peptide immunogens, we present our experience with generation of rabbit antibodies to human NOTCH3. A total of 23 antibodies were raised against 10 peptide sequences of human NOTCH3. Over 70% (16 of 23) of these polyclonal antibodies were determined to be C-terminal preferring: NOTCH3 peptide-reactive antibodies largely targeted the terminating free carboxyl group of the immunizing peptide. The antibodies that preferred C-terminal epitopes reacted weakly or not at all with recombinant target sequences with extension the C-terminus that eliminated the free carboxyl group of the immunogen structure; furthermore, each of these antisera revealed no antibody reactivity to proteins truncated before the C-terminus of the immunogen. In immunocytochemical applications of these anti-peptide antibodies, we similarly found reactivity to recombinant targets that best binding to cells expressing the free C-terminus of the immunizing sequence. In aggregate, our experience demonstrates a strong propensity for rabbits to mount antibody responses to C-terminal epitopes of NOTCH3-derived peptides which is predicted to limit their use against the native protein. We discuss some potential approaches to overcome this bias that could improve the efficiency of generation of antibodies in this commonly utilized experimental paradigm.
Funder
National Institutes of Health
U.S. Department of Veterans Affairs
Publisher
Springer Science and Business Media LLC
Reference20 articles.
1. Trier, N., Hansen, P. & Houen, G. Peptides, antibodies, peptide antibodies and more. Int. J. Mol. Sci. 20, 6289. https://doi.org/10.3390/ijms20246289 (2019).
2. Arnon, R., Maron, E., Sela, M. & Anfinsen, C. B. Antibodies reactive with native lysozyme elicited by a completely synthetic antigen. Proc. Natl. Acad. Sci. U.S.A. 68, 1450–1455. https://doi.org/10.1073/pnas.68.7.1450 (1971).
3. Chersi, A., Di Modugno, F. & Rosano, L. Aims and limitations in the use of antipeptide antibodies in molecular biology. Biol. Chem. 378, 635–640 (1997).
4. Dyson, H. J. & Wright, P. E. Antigenic peptides. FASEB J. 9, 37–42. https://doi.org/10.1096/fasebj.9.1.7821757 (1995).
5. Fieser, T. M., Tainer, J. A., Geysen, H. M., Houghten, R. A. & Lerner, R. A. Influence of protein flexibility and peptide conformation on reactivity of monoclonal anti-peptide antibodies with a protein alpha-helix. Proc. Natl. Acad. Sci. U.S.A. 84, 8568–8572. https://doi.org/10.1073/pnas.84.23.8568 (1987).